Showing posts with label swine flu. Show all posts
Showing posts with label swine flu. Show all posts

Saturday, 5 November 2011

(H1N1) virus

Putative amino acid determinants of the emergence of the 2009 influenza A (H1N1) virus in the human population

  1. Daphna Meroza,
  2. Sun-Woo Yoonb,
  3. Mariette F. Ducatezb,
  4. Thomas P. Fabriziob,
  5. Richard J. Webbyb,
  6. Tomer Hertzc,1, and
  7. Nir Ben-Tala,1
+ Author Affiliations
  1. aDepartment of Biochemistry and Molecular Biology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel 69978;
  2. bDepartment of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105; and
  3. cVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
  1. Edited by Barry Honig, Columbia University Howard Hughes Medical Institute, New York, NY, and approved July 8, 2011 (received for review October 6, 2010)

Abstract

The emergence of the unique H1N1 influenza A virus in 2009 resulted in a pandemic that has spread to over 200 countries. The constellation of molecular factors leading to the emergence of this strain is still unclear. Using a computational approach, we identified molecular determinants that may discriminate the hemagglutinin protein of the 2009 human pandemic H1N1 (pH1N1) strain from that of other H1N1 strains. As expected, positions discriminating the pH1N1 from seasonal human strains were located in or near known H1N1 antigenic sites, thus camouflaging the pH1N1 strain from immune recognition. For example, the alteration S145K (an antigenic position) was found as a characteristic of the pH1N1 strain. We also detected positions in the hemagglutinin protein differentiating classical swine viruses from pH1N1. These positions were mostly located in and around the receptor-binding pocket, possibly influencing binding affinity to the human cell. Such alterations may be liable in part for the virus’s efficient infection and adaptation to humans. For instance, 133A and 149 were identified as discriminative positions. Significantly, we showed that the substitutions R133AK and R149K, predicted to be pH1N1 characteristics, each altered virus binding to erythrocytes and conferred virulence to A/swine/NC/18161/02 in mice, reinforcing the computational findings. Our findings provide a structural explanation for the deficient immunity of humans to the pH1N1 strain. Moreover, our analysis points to unique molecular factors that may have facilitated the emergence of this swine variant in humans, in contrast to other swine variants that failed.

Friday, 19 August 2011

(H1N1) virus


Putative amino acid determinants of the emergence of the 2009 influenza A (H1N1) virus in the human population

  1. Daphna Meroza,
  2. Sun-Woo Yoonb,
  3. Mariette F. Ducatezb,
  4. Thomas P. Fabriziob,
  5. Richard J. Webbyb,
  6. Tomer Hertzc,1, and
  7. Nir Ben-Tala,1

+ Author Affiliations

  1. aDepartment of Biochemistry and Molecular Biology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel 69978;
  2. bDepartment of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105; and
  3. cVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
  1. Edited by Barry Honig, Columbia University Howard Hughes Medical Institute, New York, NY, and approved July 8, 2011 (received for review October 6, 2010)

Abstract

The emergence of the unique H1N1 influenza A virus in 2009 resulted in a pandemic that has spread to over 200 countries. The constellation of molecular factors leading to the emergence of this strain is still unclear. Using a computational approach, we identified molecular determinants that may discriminate the hemagglutinin protein of the 2009 human pandemic H1N1 (pH1N1) strain from that of other H1N1 strains. As expected, positions discriminating the pH1N1 from seasonal human strains were located in or near known H1N1 antigenic sites, thus camouflaging the pH1N1 strain from immune recognition. For example, the alteration S145K (an antigenic position) was found as a characteristic of the pH1N1 strain. We also detected positions in the hemagglutinin protein differentiating classical swine viruses from pH1N1. These positions were mostly located in and around the receptor-binding pocket, possibly influencing binding affinity to the human cell. Such alterations may be liable in part for the virus’s efficient infection and adaptation to humans. For instance, 133A and 149 were identified as discriminative positions. Significantly, we showed that the substitutions R133AK and R149K, predicted to be pH1N1 characteristics, each altered virus binding to erythrocytes and conferred virulence to A/swine/NC/18161/02 in mice, reinforcing the computational findings. Our findings provide a structural explanation for the deficient immunity of humans to the pH1N1 strain. Moreover, our analysis points to unique molecular factors that may have facilitated the emergence of this swine variant in humans, in contrast to other swine variants that failed.

Thursday, 10 February 2011

Swine flu narcolepsy 'link' probed by WHO

H1N1 virus More than 30 million doses of swine flu vaccine have been given in Europe

Related Stories

At least 12 countries have reported a possible link between a swine flu jab and a rare sleeping disorder, the World Health Organization has confirmed.

It said "further investigation was warranted" following reports of 52 cases of narcolepsy linked to the Pandemrix jab in Finland.

Cases have also been reported in Sweden, Iceland and the UK.

The government agency which regulates medicines in the UK said a link had not been confirmed.

The Medicines and Healthcare products Regulatory Agency (MHRA) said: "The Pandemrix vaccine remains available and should continue to be used as recommended.

"The benefits of vaccination outweigh any risk of a possible side effect."

Narcolepsy is a rare condition where a person falls asleep suddenly and unexpectedly.

A possible connection between the swine flu vaccine and the illness first came to light in Finland.

Finland and other Scandinavian countries have reported a general rise in cases of narcolepsy - in both vaccinated and unvaccinated people - but the cause has not been established.

UK cases

A recent investigation by Finnish authorities found children given the swine flu jab Pandemrix were about nine times more likely to develop narcolepsy than those who had not been vaccinated.

The WHO's global advisory committee on vaccine safety reviewed this, and other data, last week.

Narcolepsy

  • Narcolepsy is a rare illness, with around 10 new cases per million people every year
  • The main symptom is falling asleep suddenly
  • The cause of narcolepsy remains unclear
  • Some people may be predisposed to the condition by their genetics
  • Suggested initial triggers include infections such as measles or mumps, accidents and the hormonal changes that take place in puberty
  • It most often begins between the ages of 15 and 30

It said the committee would continue to monitor the situation and agrees that "further investigation is warranted concerning narcolepsy and vaccination against influenza (H1N1) 2009 with Pandemrix and other pandemic H1N1 vaccines".

The WHO said an increased risk of narcolepsy had not been observed with any other vaccines - for flu or other diseases - in the past.

It said: "Even at this stage, it does not appear that narcolepsy following vaccination against pandemic influenza is a general worldwide phenomenon and this complicates interpretation of the findings in Finland."

The Pandemrix vaccine, made by Glaxo Smith Kline, has been used in 47 countries following the swine flu outbreak last year.

More than six million doses of the H1N1 vaccine have been given in the UK, with more than 30 million given across Europe.

The MHRA said it had received four unconfirmed reports of narcolepsy following vaccination.

It said the reports so far in the UK "are no more than we would expect to see by coincidence after vaccination".

More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites

Friday, 24 December 2010

Swine flu vaccine safety probed over link to rare sleep disorder

Swine flu vaccine safety probed over link to rare sleep disorder

The safety of a swine flu vaccine is to be investigated by European drugs regulators after it was linked to a rare condition that causes people to fall asleep suddenly.

An investigation has been launched after a swine flu vaccine was linked to a condition that causes people to fall asleep suddenly.
An investigation has been launched after a swine flu vaccine was linked to a condition that causes people to fall asleep suddenly. Photo: Getty Images

The investigation has been prompted after health officials in Finland announced they were suspending the vaccination programme there following reports of narcolepsy in people who had received the jab.

So far there have been 27 reports of suspected narcolepsy in people across Europe who had previously been vaccinated with Pandemrix, the H1N1 swine flu vaccine made by GlaxoSmithKline.

No cases have been reported in Britain.

In total more than 30m people in the European Union have been vaccinated with Pandemrix.

Narcolepsy is a rare condition and its causes are unknown. It can be dangerous if sufferers fall asleep while driving or operating machinery. It is thought there are 25,000 people with the condition in Britain but experts have estimated that 80 per cent of sufferers have not been diagnosed.

Once diagnosed with the condition, which is long-term and has no cure, people are not allowed to drive.

The investigation will examine if Pandemrix was the likely trigger for the condition or whether it was a coincidence.

Finland suspended its national vaccination programme on Tuesday after eight suspected cases of narcolepsy following administration of the jab. A further ten cases have been reported in Sweden, six in France, and one each in Germany and Norway.

The European Medicines Agency will now investigate if there is any link, including how many people would normally be expected to suffer narcolepsy so this 'background rate' can be compared to with the number of cases observed after vaccination.

The Agency is also liaising with the European Centre for Disease Prevention and Control, other drugs regulators and the World Health Organisation.

A spokesman for GlaxoSmithKline said: "Information surrounding the reported cases remains limited at the current time. GSK is conducting its own investigation in an effort to gather as much additional data as possible regarding the observed cases and is working closely with the regulatory authorities, including the European Medicines Agency (EMA)

"Global experience with previous large-scale immunisation programmes has shown that it is likely that a certain level of adverse events will be reported. The adverse events that are reported may be the result of underlying conditions, or new conditions that occur in temporal association with the vaccination, and some events may be related to the vaccine.

"Having reviewed the currently available data and information regarding the reported cases of narcolepsy, which remains limited at this time, as well as GSK’s own safety database, the Company has concluded that the currently available information is insufficient to assess the likelihood of a causal relationship between Pandemrix and narcolepsy."

Featured post

More patients in Scotland given antidepressants

More patients in Scotland given antidepressants 13 October 2015   From the section Scotland Image copyright Thinkstock Image ca...